Iteris - ITI Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iteris in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITI shares.
View ITI analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year price objectives for Iteris' stock. Their ITI share price forecasts range from $3.00 to $6.00. On average, they expect the company's share price to reach $4.50 in the next twelve months.
View analysts price targets for ITI or view top-rated stocks among Wall Street analysts.

Iteris' stock was trading at $3.11 on January 1st, 2023. Since then, ITI stock has increased by 44.7% and is now trading at $4.50.
View the best growth stocks for 2023 here.

Iteris saw a increase in short interest in February. As of February 28th, there was short interest totaling 199,200 shares, an increase of 8.5% from the February 13th total of 183,600 shares. Based on an average daily volume of 93,400 shares, the short-interest ratio is currently 2.1 days.
View Iteris' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 7th 2023.
View our ITI earnings forecast.

Iteris, Inc. (NASDAQ:ITI) issued its quarterly earnings data on Thursday, February, 2nd. The technology company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The technology company earned $40.69 million during the quarter, compared to analyst estimates of $37.83 million. Iteris had a negative trailing twelve-month return on equity of 24.92% and a negative net margin of 11.79%.

Iteris updated its fourth quarter 2023 earnings guidance on Thursday, February, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $39.40 million-$41.40 million, compared to the consensus revenue estimate of $41.40 million.

9 employees have rated Iteris Chief Executive Officer Joe Bergera on Glassdoor.com. Joe Bergera has an approval rating of 100% among the company's employees. This puts Joe Bergera in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iteris investors own include Energy Transfer (ET), Ford Motor (F), Advanced Micro Devices (AMD), Inseego (INSG), Nokia Oyj (NOK), Novavax (NVAX), OPKO Health (OPK), Strongbridge Biopharma (SBBP), CBL & Associates Properties (CBL) and Enphase Energy (ENPH).

Iteris trades on the NASDAQ under the ticker symbol "ITI."

Iteris' stock is owned by many different retail and institutional investors. Top institutional investors include Cowen Prime Advisors LLC (8.15%), Samjo Capital LLC (7.69%), Private Management Group Inc. (4.67%), Dimensional Fund Advisors LP (2.41%), First Eagle Investment Management LLC (1.20%) and Acuitas Investments LLC (0.91%). Insiders that own company stock include Douglas L Groves, Gerard Mooney, J Joseph Bergera, Ramin M Massoumi, Santiago Subotovsky, Todd Kreter and Tom Thomas.
View institutional ownership trends.

Shares of ITI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITI stock can currently be purchased for approximately $4.50.

Iteris (NASDAQ:ITI) has a market capitalization of $192.47 million and generates $133.57 million in revenue each year. The technology company earns $-7,080,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

The company employs 415 workers across the globe.

Iteris' mailing address is 1700 CARNEGIE AVENUE, SANTA ANA CA, 92705. The official website for the company is www.iteris.com. The technology company can be reached via phone at (512) 716-0808, via email at iti@mkr-group.com, or via fax at 949-270-9401.